Why is retatrutide written as Reta, LY3437943, or triple agonist?

They are the same compound. Retatrutide is the international non-proprietary name used in peer-reviewed literature and FDA filings. LY3437943 is Eli Lilly’s developmental code, still found in older papers and trial-registry entries. "Reta" is community shorthand with no scientific currency. "Triple agonist" is a functional descriptor of the receptor profile.

How does retatrutide differ from semaglutide and tirzepatide?

Receptor count. Semaglutide is a GLP-1 receptor agonist. Tirzepatide adds GIP, making it a dual agonist. Retatrutide adds glucagon on top of both, making it a triple agonist. The published Phase 2 data for each is not directly comparable across trials with different designs.

Is retatrutide an approved medicine?

No. It is investigational. Phase 2 trial data has been published in obesity and type 2 diabetes, but it has not completed the approval process, and nothing on this page should be read as a recommendation to use it.

Can I get retatrutide without a consultation?

Not through us. The assessment is the point: an investigational triple agonist is not something to start on the strength of a web page.

Metabolic · Rx onlyRET—04

Retatrutide

reh·tah·TROO·tideGLP-1 / GIP / glucagon — triple agonist

Physician-managed weight therapy — structured check-ins, nutrition guidance, and dose titration set by your doctor, not a dropdown.

Once weekly12+ weeks, titratedLabs wk 1 · 6 · 12Physician-supervised

Check your eligibility Read the clinical reference →

The evidence−24.2%

Mean body-weight change at 48 weeks on the highest dose — the largest reported in the class. N Engl J Med, 2023.

Candidacy

Who this is for

Adults with obesity, significant overweight with complications, or fatty liver disease — where a genuine metabolic indication exists. Candidacy is decided by your physician against your history and labs, never by a checkout flow.

Often appropriateBMI above 27 with a metabolic complicationFatty liver disease confirmed on imaging or labsStructured diet and training already attempted

Not appropriatePersonal or family history of medullary thyroid carcinoma or MEN2Pregnancy, breastfeeding, or planning conceptionHistory of pancreatitis without specialist review

Built for functionWeight is the metric. Capacity is the point.

The program

How the program works

Day 0Free video consultation

A PRC-licensed physician reviews your goals, history, and whether this therapy is appropriate. If it isn't, you'll hear that instead.

Week 1Baseline labs & first dose

An at-home blood draw establishes your baseline. Your pen ships cold-chain once your physician signs the prescription.

Weeks 2–12Titration & check-ins

Dose steps up every four weeks as tolerated, with a video review at each step and messaging in between.

Week 12Full review

Repeat labs against your baseline. Together you decide: continue, adjust, or taper off with a plan.

Included

What’s included

Single-patient pen, named prescriptioncGMP facility

Cold-chain delivery to your door1–2 days, Metro Manila

Baseline and repeat lab panelsweeks 1, 6, 12

Video reviews at every dose stepnamed physician

Nutrition and training guidanceevery check-in

No prices on this site by design — your program is quoted in full after your consultation, before anything is dispensed.

Questions

Common questions

In the phase 2 trial, weight loss was progressive across 48 weeks and had not plateaued at study end. Your physician tracks your response at every review — expectations are set against your baseline, not someone else's before-and-after.

Find out if this fits youFree 20-min video consultation

Book

The science

Three receptors, one peptide

GLP-1 receptor agonism

The most extensively characterised pathway in the incretin class. GLP-1 receptor engagement drives glucose-dependent insulin secretion, modulates gastric emptying, and acts on central appetite signalling. Forms the mechanistic backbone of every approved and investigational incretin compound.

GIP receptor agonism

Glucose-dependent insulinotropic polypeptide receptor activation. Preclinical research indicates GIP agonism contributes to lipid metabolism in adipose tissue and insulin sensitivity at effects not consistently observed with GLP-1 alone. Tirzepatide established the dual GLP-1/GIP architecture commercially; retatrutide retains it.

Glucagon receptor agonism

The mechanistic distinction that sets retatrutide apart in its class. Glucagon receptor activation increases hepatic glucose output in isolation, but combined with GLP-1 and GIP co-agonism the insulinotropic effects offset the glycemic impact while hepatic fat metabolism and thermogenic energy expenditure effects are preserved.

Balanced receptor engagement

In vitro pharmacology characterised by Coskun and colleagues (Cell Metab, 2022;34(9):1234-1247) reports that LY3437943 shows balanced glucagon and GLP-1 receptor activity with relatively greater GIP receptor activity, providing the ratio that underpins the compound’s downstream metabolic profile in published trials.

Retatrutide is also searched as LY3437943, Reta, Triple agonist.

References

Coskun T, et al. LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist. Cell Metab. 2022;34(9):1234-1247.

Reta­trutide